Tom Newsom-Davis

There is healthy skepticism and there is this...

a man with a beard is standing in front of a microphone scratching his head ALT: a man with a beard is standing in front of a microphone scratching his head

Going through applications for BTOG Trainee Representatives in oncology and respiratory medicine

The most extraordinary group of dynamic, motivated, committed individuals

So impressive
So hard to decide
Every single one would be excellent

On our next livestreams: a look at how #LungCancer affects young people and women, with moderator Dr. Isabel Preeshagul.

Wed, April 23: Young Lung Cancer w/ Dr. Eric Singhi @lungoncdoc.bsky.social, LCRF.org/together2
Wed, May 14: Women & Lung Cancer w/ Dr. Narjust Florez, LCRF.org/together

Exciting news!
@curetoday.bsky.social is hosting an incredible Young-Onset Lung Cancer Summit 🎉 Chaired by the amazing
@lungoncdoc.bsky.social, this is a must-attend event for anyone looking to learn more about @younglungcancer.bsky.social!

Happy to share our latest work, led by Dr Monaca. In a time-dependent analysis, we show that irAEs are associated with improved outcomes in ES-SCLC. Interestingly, neither high-grade irAEs nor the use of steroids appeared to negatively impact survival. www.sciencedirect.com/science/arti...

Not only does ‘Repositories of Agriculture’ debase scientific publications through unsolicited paper requests, but they then get aggressive when you don’t reply.

Extraordinary

Think they need to review their PR skills (and conscience)

When the conference organizers ask if you can send in your slides a week in advance

❗️FLAURA2 approved by NICE❗️

Already on BlueTeq!

Now an option for 1L EGFR+ pts

Worth familiarising yourself with the higher risk subgroups that seemed to better with this regimen

🏴󠁧󠁢󠁳󠁣󠁴󠁿?

❗️BTOG / NLCA ‘State of the Nation’ webinar on 15th May❗️

The National Lung Cancer Audit has been instrumental in improvement of lung cancer outcomes in UK

Come and hear about our successes and challenges. Neal Navani always gives a beautifully clear and concise talk. 👍

This is an excellent series of discussions. Informed and informative. Highly recommend it.

@katherinesleeman.bsky.social especially good, as she is always.

Very important dataset and a set forward to potential ambulatory delivery in the future.

🧐 Are you a 🇬🇧 Healthcare Professional treating lung cancer?

🤔 Do you want to learn how clinical research runs, whilst advancing your career?

💥 Be an Associate PI of a trial!

🥳 eVOLVE-Lung02 (I am 🇬🇧 CI) accepted into NIHR Associate PI programme

Details here 👇
www.nihr.ac.uk/career-devel...

UK Oncologist’s Garden:

The pear trees are just in blossom

What!? Tiramisu is younger than my dad? Also the 1940s saw great additions to our cuisine. Weird how young ciabatta is! Fun chart shows several foods that were invented surprisingly recently. Source: buff.ly/nvQgUns

Wow
Extraordinary times

‘No evidence that patient survival is improved with surgery’

Curious wording from NCCN, given that MARS2 found that epithelioid histology pts had 12% higher risk of death if they had surgery…

New data from the LAURA trial shared at #ELCC25 today shows promising results for Stage 3 unresectable EGFR+ #lungcancer.

Giving osimertinib after chemoradiation meant people went much longer before needing further treatment — over 40 months, compared to just 9 months without it. #LCSM

Predicting surgical complexity following neo-adjuvant chemoIO

Single centre 🇬🇧 study

👉 43% defined as complex

🔺 Risk score includes x3 variables:
❇️ CN2
❇️ Absence of nodal response
❇️ PD-L1 >50%

#ELCC25

LAURA OS update (LBA4)
👉 Now 31% maturity

❇️ 78% in PBO grp got Osi at PD
❇️ Improved PFS2
❇️ Trend ⬆️ OS HR 0.67, not significant

💭 Confirm activity of Osi
💭 Crossover impacts OS difference
💭 Final maturity due @ 60%
💭 Surprised 1/3 Osi pts = no further treatment at PD

#ELCC25

2) daraxonrasib (rmc-6236) offering early phase and v impressive activity in g12d g12v 2nd line nsclc. RR 38% and mPFS >10m. V tolerable toxicity profile again. Next will be IO combos, congrats+++ to Revolution Medicines and the investigators. #ELCC25

1) KRYSTAL-7 update on pembro+adagrasib in 1st line pdl1 >50% nsclc. Tox to navigate but mPFS >27m! Further reinforcing the view that ras orchestrates TME, not just cancer cell intrinsic pathways. Massive congrats to investigators, mirati, bms #ELCC25

Great ROS1 TKI summary slide from Julian Mazieres

COCOON: mitigating cutaneous toxicity of Amivantamab

✅ 60% reduction in Gr2+ dermatology AE
✅ Reduction scalp issues+ paronychia
✅ Fewer Ami dose amendments needed

💭 This regimen should be instigated immediately for any patient starting Amivantamab based therapy

#ELCC25

Case controlled indirect comparison of Taletrectinib v Crizotinib in ROS1 NSCLC

👉 From TRUST I + II / PROFILE 1091 trials
✅ ORR 90% v 71%
✅ Improved PFS, HR 0.48
👉 Similar Gr3 TRAEs

💭 Ph3 head-2-head ongoing
💭 In meanwhile, this suggests Taletrectinib superior
💭 Would like to see CNS data

#ELCC25

Tobemstomig (LAG3/PD1 bispecific) + chemo in 1L NSCLC

👉 Randomised Ph2
❌ No ORR benefit
❌ No PFS benefit
❌ Higher Gr3+ TRAEs

💭 Not active combination
💭 Reality check on growing bispecific excitement
💭 Disappointing. LAG3 is hard to target.

#ELCC25

Pan-KRASi: RMC-6236

👉 NSCLC pts from Ph1 study
❇️ 200mg = Ph3 dose
❗️TRAE: mucocutaneous, GI, liver
❗️ Rash prophylaxis needed
👉 Clinical data from G12X popn:
❇️ ORR 38%
❇️ mPFS = 9.8m

Ph3 RASolve-301 underway

💭 Need breakdown by mutant type
💭 Press release: safe combo w Pembro

#ELCC25

🇬🇧 healthcare has many challenges & shortcomings

But we lead the world in lung cancer screening (many of these pioneers being on this paper)

Now in routine clinical practice, causing stage shift. I see the effects every week.

We need to bang the drum more about this 🥁

ORCHARD (module 10): Osi + Dato-Dxd post 1L Osi

❇️ ORR 36 - 43%
❇️ mPFS 9.5 - 11.7m
❇️ DoR longer in 6mg/kg grp

❗️ 65% Dato dose reduction
❗️ 60% Dato dose interr

💭 Active combination
💭 Toxic+
💭 Not biomarker directed

#ELCC25

BAY88 in HER2mut NSCLC

Lower ORR, but similar DoR, if prior HER2 ADC (as opposed to treatment naive)

#ELCC25